Evidence map›Paper›PMID 40259941›Full record

ArticleJournal of biomedical physics & engineering2025

Innovative Approach for Diabetic Retinopathy Severity Classification: An AI-Powered Tool using CNN-Transformer Fusion.

Khosro Rezaee, Fateme Farnami

Abstract read
In one paragraph

Article in Journal of biomedical physics & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Khosro RezaeeDepartment of Biomedical Engineering, Meybod University, Meybod, Iran.
Fateme FarnamiDepartment of Biomedical Engineering, Hakim Sabzevari University, Sabzevar, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetic retinopathy (DR), a diabetes complication, causes blindness by damaging retinal blood vessels. While deep learning has advanced DR diagnosis, many models face issues like inconsistent performance, limited datasets, and poor interpretability, reducing their clinical utility. Objective: This research aimed to develop and evaluate a deep learning structure combining Convolutional Neural Networks (CNNs) and transformer architecture to improve the accuracy, reliability, and generalizability of DR detection and severity classification. Material and Methods: This computational experimental study leverages CNNs to extract local features and transformers to capture long-range dependencies in retinal images. The model classifies five types of retinal images and assesses four levels of DR severity. The training was conducted on the augmented APTOS 2019 dataset, addressing class imbalance through data augmentation techniques. Performance metrics, including accuracy, Area Under the Curve (AUC), specificity, and sensitivity, were used for metric evaluation. The model's robustness was further validated using the IDRiD dataset under diverse scenarios. Results: The model achieved a high accuracy of 94.28% on the APTOS 2019 dataset, demonstrating strong performance in both image classification and severity assessment. Validation on the IDRiD dataset confirmed its generalizability, achieving a consistent accuracy of 95.23%. These results indicate the model's effectiveness in accurately diagnosing and assessing DR severity across varied datasets. Conclusion: The proposed Artificial intelligence (AI)-powered diagnostic tool improves diabetic patient care by enabling early DR detection, preventing progression and reducing vision loss. The proposed AI-powered diagnostic tool offers high performance, reliability, and generalizability, providing significant value for clinical DR management.

Indexed as

Artificial IntelligenceConvolutional Neural NetworksDeep LearningDiabetic RetinopathyFundus Oculi

Identifiers

PMID40259941
PMCPMC12009469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.